Boston Scientific Corp.

Boston Scientific's RSI of 33.5 signals potential oversold conditions, yet the stock commands a premium P/E of 23.55 relative to surgical instrument peers, suggesting the market remains bullish on growth prospects despite recent weakness. With short interest at just 1.73% and the company sitting below its 52-week high, there's limited squeeze risk and room for mean reversion. The valuation-to-momentum disconnect—expensive multiple combined with depressed momentum—implies either a near-term bounce or sustained pressure if fundamentals deteriorate further. The $91.8B market cap provides institutional liquidity, but the elevated P/E in a potentially cooling medtech environment warrants monitoring earnings quality and guidance.